These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35268759)

  • 41. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.
    Mahey N; Tambat R; Chandal N; Verma DK; Thakur KG; Nandanwar H
    Microbiol Spectr; 2021 Dec; 9(3):e0095121. PubMed ID: 34908453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
    Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
    Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of subinhibitory concentrations of fluoroquinolones on biofilm production by clinical isolates of Streptococcus pyogenes.
    Balaji K; Thenmozhi R; Pandian SK
    Indian J Med Res; 2013 May; 137(5):963-71. PubMed ID: 23760384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
    Prasad SV; Ballal M; Shivananda PG
    Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
    Nesar S; Shoaib MH; Rahim N; Rehman R
    Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.
    Yoshizumi S; Takahashi Y; Watanabe Y; Okezaki E; Ishii Y; Tateda K
    Chemotherapy; 2004 Dec; 50(6):265-75. PubMed ID: 15608441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J; Dubreuil L; Jumas-Bilak E
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibacterial activity and action mode of Cu(I) and Cu(II) complexes with phosphines derived from fluoroquinolone against clinical and multidrug-resistant bacterial strains.
    Guz-Regner K; Komarnicka UK; Futoma-Kołoch B; Wernecki M; Cal M; Kozieł S; Ziółkowska A; Bugla-Płoskońska G
    J Inorg Biochem; 2020 Sep; 210():111124. PubMed ID: 32534287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
    Ko WC; Chiang SR; Lee HC; Tang HJ; Wang YY; Chuang YC
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2217-22. PubMed ID: 12821471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
    Smith BR; LeFrock JL; Donato JB; Joseph WS; Weber SJ
    Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protease-Sensitive Inhibitory Activity of Cell-free Supernatant of Lactobacillus crispatus 156 Synergizes with Ciprofloxacin, Moxifloxacin and Streptomycin Against Pseudomonas aeruginosa: An In Vitro Study.
    Kaur S; Sharma P
    Probiotics Antimicrob Proteins; 2015 Jun; 7(2):172-80. PubMed ID: 25693845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
    Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
    Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative mutant prevention concentration and antibacterial activity of fluoroquinolones against Escherichia coli in diarrheic buffalo calves.
    Beri S; Sidhu PK; Kaur G; Chandra M; Rampal S
    J Chemother; 2015 Oct; 27(5):312-6. PubMed ID: 24575977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.